Our data suggest that SCLC patients with ASCL1 and NEUROD1 NOTCH1-ICD–positive tumors may be an immunotherapy-sensitive population and that the addition of a STING agonist with anti–PD-L1 therapy may enhance antitumor immune response in this population. This evidence concerns the gene CD274 and small cell lung carcinoma.